Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amifampridine - Jacobus Pharmaceutical

Next Previous
Search
Drug Profile

Amifampridine - Jacobus Pharmaceutical

Alternative Names: 3-4DAP; Ruzurgi

Latest Information Update: 16 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jacobus Pharmaceutical
  • Developer Jacobus Pharmaceutical; Medunik Canada; ORSPEC Pharma
  • Class Aminopyridines; Antineoplastics; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lambert-Eaton myasthenic syndrome
  • New Molecular Entity No

Highest Development Phases

  • Registered Lambert-Eaton myasthenic syndrome

Most Recent Events

  • 12 Jul 2022 Catalyst Pharmaceuticals in-licenses development and marketing rights for Amifampridine from Jacobus Pharmaceutical in USA and Mexico
  • 12 Jul 2022 Catalyst Pharmaceuticals settled its patent infringement litigation against Jacobus Pharmaceutical Company and PANTHERx Rare over related patent rights in the marketing and distribution of amifampridine in US and Mexico
  • 10 Mar 2022 Withdrawn for Lambert-Eaton myasthenic syndrome (In adolescents, In children, In the elderly, In adults) in Canada (PO), as it is no longer authorised for sale in Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top